Clinical effectiveness of 8% capsaicin dermal patch in neuropathic pain - noninterventional real-life clinical study in Czech Republic
Abstract
Capsaicin dermal patch is an adhesive patch containing a high concentration (8%) of synthetic capsaicin. It is indicated for the treatment of peripheral neuropathic pain in non-diabetic adults.
In this prospective, multicentre, open, single-arm, non-interventional real-life clinical trial 214 patients (28-91 years) were treated with 60-min application of 8% capsaicin dermal patch. Capsaicin dermal patch reduced the mean NPRS scores from baseline 6,8 points to 4,4 points after 3 months of treatment (p<0,001).
More than half of patients (52%) had a 30% or greater reduction in mean NPRS score. The quality of life assessed by EQ-5D questionnaire has significantly improved (from 0,509 to 0,626; p<0,001) and the consumption of concomitant antineuropathic medication has decreased (96,2% of patients at baseline to 79,7% after 3 months).
Patients treated with capsaicin dermal patch have lower rate of hospital admissions and shorter length of stay. Capsaicin dermal patch was well tolerated.
The most common adverse events were transient, mostly mild to moderate, application-site reactions in 6% of patients.